Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

• Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
• A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
• BDB-001 Phase III Trial in ANCA-Associated Vasculitis
• Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
• A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
• A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
• Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis
• SGLT-2 Inhibitors on Albuminuria in Chronic Kidney Disease Patients With Lupus Nephritis and ANCA- Associated Vasculitis
• Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
• Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)
• A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
• BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
• Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
• NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)
• The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN)
• Anti-CD19 IL-10 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
• Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
• Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
• A Study of RD06-04 in Patients With Active Autoimmune Diseases
• Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
• IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy
• Iptacopan in Patients With ANCA Associated Vasculitis
• A Phase 1 Study of ADI-001 in Autoimmune Disease
• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
• The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
• Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
• Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
• A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
• A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
• The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects
• ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
• PR3-AAV Resilient Remission or PRRR
• Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
• Effect of Tofacitinib in Treating ANCA-associated Vasculitis
• Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
• Comparison of the Efficacy of Leflunomide and Azathioprine for the Maintenance Therapy of ANCA Associated Vasculitis
• Hydroxychloroquine in ANCA Vasculitis Evaluation
• Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
• Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis
• Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease
• Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy
• A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
• Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
• Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
• The Clinical Efficacy of DFPP in Patients With AAGN
• Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
• Low-dose Glucocorticoid Vasculitis Induction Study
• Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
• Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)
• Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
• Rituximab Vasculitis Maintenance Study
• CMV Modulation of the Immune System in ANCA-associated Vasculitis
• Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
• Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens
• Efficacy Study of Two Treatments in the Remission of Vasculitis
• Abatacept in ANCA Associated Vasculitis
• Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
• WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
• MMF Versus CTX in the Induction Treatment of ANCA Associated Vasculitis
• Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis
• Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
• Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
• Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)